Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

Blood
Rami S KomrokjiRuben A Mesa

Abstract

Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1. It demonstrated a favorable safety profile with promising efficacy in phase 1 studies in patients with primary and secondary myelofibrosis (MF). This multicenter phase 2 study further characterized the safety and efficacy of pacritinib in the treatment of patients with MF. Eligible patients had clinical splenomegaly poorly controlled with standard therapies or were newly diagnosed with intermediate- or high-risk Lille score. Patients with any degree of cytopenia were eligible. Thirty-five patients were enrolled. At entry, 40% had hemoglobin <10 g/dL and 43% had platelets <100 000× 10(9)/L. Up to week 24, 8 of 26 evaluable patients (31%) achieved a ≥35% decrease in spleen volume determined by magnetic resonance imaging and 14 of 33 (42%) attained a ≥50% reduction in spleen size by physical examination. Median MF symptom improvement was ≥50% for all symptoms except fatigue. Grade 1 or 2 diarrhea (69%) and nausea (49%) were the most common treatment-emergent adverse events. The study drug was discontinued in 9 patients (26%) due to adverse events (4 severe). Pacritinib is an active agent in patients wit...Continue Reading

References

Mar 23, 2005·Lancet·E Joanna BaxterUNKNOWN Cancer Genome Project
Apr 29, 2005·The New England Journal of Medicine·Robert KralovicsRadek C Skoda
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naseema GangatAyalew Tefferi
Jan 4, 2012·Mayo Clinic Proceedings·Ayalew TefferiAnimesh Pardanani
Mar 2, 2012·The New England Journal of Medicine·Claire HarrisonGiovanni Barosi
Mar 2, 2012·The New England Journal of Medicine·Srdan VerstovsekHagop M Kantarjian
Sep 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesJoy Zhu
Oct 17, 2012·Cancer Control : Journal of the Moffitt Cancer Center·Rami S KomrokjiAlan F List
Dec 12, 2013·The New England Journal of Medicine·Thorsten KlampflRobert Kralovics

❮ Previous
Next ❯

Citations

Oct 20, 2015·Pharmacology & Therapeutics·Edna Zhi Pei ChaiGautam Sethi
Sep 22, 2015·Expert Opinion on Pharmacotherapy·Yan BeauverdClaire N Harrison
Jul 15, 2015·Expert Opinion on Emerging Drugs·Holly L Geyer, Ruben A Mesa
Oct 23, 2015·Critical Reviews in Oncology/hematology·Matthieu Cornelis Johannes BosmanEdo Vellenga
Feb 4, 2016·The Cancer Journal·Sonia CerquozziAyalew Tefferi
Oct 23, 2015·American Journal of Hematology·Ayalew Tefferi
Feb 19, 2016·Expert Review of Hematology·Francisco CervantesJuan Carlos Hernandez-Boluda
Sep 29, 2015·Current Hematologic Malignancy Reports·Naveen PemmarajuMichael A Thompson
Aug 19, 2015·Current Hematologic Malignancy Reports·Giovanni Barosi
Sep 15, 2015·Future Oncology·Srdan Verstovsek, Rami S Komrokji
Apr 2, 2016·Medicina clínica·Juan Carlos Hernández BoludaAriadna Pérez
Jun 16, 2015·British Journal of Haematology·Clodagh KeohaneGhulam J Mufti
Apr 20, 2016·Experimental Hematology·Olaya Santiago-FernándezCarlos López-Otín
May 23, 2016·Annals of Hematology·Haifa Kathrin Al-Ali, Alessandro M Vannucchi
May 18, 2016·Expert Opinion on Drug Safety·J M O'SullivanC N Harrison
Jun 29, 2016·Cytokine·Jan PencikLukas Kenner
Nov 9, 2011·Clinical Lymphoma, Myeloma & Leukemia·Fabio P S Santos, Srdan Verstovsek
Aug 12, 2016·Hematological Oncology·Francesca PalandriMichele Baccarani
Aug 20, 2016·Annals of Hematology·Lindsey ShantzerJeffrey J Pu
Oct 19, 2016·Expert Review of Anticancer Therapy·Tania Jain, Ruben Mesa
Nov 2, 2016·Expert Opinion on Investigational Drugs·Prithviraj Bose, Srdan Verstovsek
Apr 27, 2017·Expert Opinion on Investigational Drugs·Prithviraj BoseSrdan Verstovsek
Jun 3, 2017·Expert Review of Hematology·Iram SaeedClaire N Harrison
Jul 6, 2017·Journal of Cellular and Molecular Medicine·Suzanne McPhersonKen Mills
May 14, 2017·Blood·Prithviraj Bose, Srdan Verstovsek
Jun 3, 2017·Blood·Eric Solary, Raphael Itzykson
Feb 7, 2018·Nature Reviews. Clinical Oncology·Daniel E JohnsonJennifer R Grandis
Jun 6, 2017·Clinical Medicine Insights. Blood Disorders·Alessandra Iurlo, Daniele Cattaneo
Nov 4, 2017·Current Hematologic Malignancy Reports·Kristen Pettit, Olatoyosi Odenike
Nov 15, 2017·Expert Opinion on Pharmacotherapy·Martin Griesshammer, Parvis Sadjadian
Aug 20, 2015·Therapeutic Advances in Hematology·Ana B Duenas-Perez, Adam J Mead
Jul 13, 2018·Expert Review of Hematology·Douglas Tremblay, John Mascarenhas
Aug 8, 2018·International Journal of Molecular Sciences·Moses M KasembeliDavid J Tweardy
Sep 13, 2019·Blood Cancer Journal·Michael SchieberBrady Stein
May 1, 2020·Current Treatment Options in Oncology·Alessandra IurloCristina Bucelli
Oct 25, 2016·Expert Opinion on Pharmacotherapy·Prithviraj Bose, Srdan Verstovsek
Dec 10, 2016·Journal of Hematology & Oncology·Srdan VerstovsekH Joachim Deeg
Aug 10, 2017·Drugs·Douglas TremblayJohn Mascarenhas
Sep 10, 2020·HemaSphere·Prithviraj Bose, Srdan Verstovsek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.